Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that the China National Medical Products Administration (NMPA) has granted marketing approval for its Insulin Degludec and Insulin Aspart Injection, a dual insulin analogue combining ultra‑long‑acting basal and rapid‑acting prandial insulin in a single formulation. The approval covers two delivery formats – cartridge type and pre‑filled pen type – broadening patient access across clinical settings.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New Drug Marketing Authorization |
| Product | Insulin Degludec and Insulin Aspart Injection |
| Delivery Formats | Cartridge type; Pre‑filled pen type |
| Composition | 70 % insulin degludec (basal) + 30 % insulin aspart (prandial), fixed 7:3 ratio |
| Indication | Blood glucose control in patients requiring insulin therapy (fasting and postprandial) |
| Approval Date | 8 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: Dual insulin analogue – a fixed‑ratio combination of two recombinant human insulin analogues
- Basal Component (70 %): Insulin degludec – an ultra‑long‑acting basal insulin that forms soluble multi‑hexamers after subcutaneous injection, providing stable, peakless insulin release over >24 hours for consistent fasting and baseline blood glucose control
- Prandial Component (30 %): Insulin aspart – a rapid‑acting insulin analogue with fast onset of action, designed to effectively suppress postprandial blood glucose spikes following meals
- Formulation Innovation: The two components remain independently stable within a single formulation with no mutual interference in pharmacological activity, a critical formulation achievement that preserves the distinct pharmacokinetic profiles of each insulin
- Clinical Advantage: A single injection addresses both fasting (basal) and postprandial (prandial) blood glucose control, potentially simplifying treatment regimens and improving patient adherence compared to separate basal‑bolus insulin administrations
Clinical Context – Dual Insulin Analogue Class
| Feature | Insulin Degludec/Aspart (70/30) | Traditional Basal‑Bolus Regimen |
|---|---|---|
| Injection Frequency | Reduced (single formulation covers both needs) | Multiple daily injections (separate basal + bolus) |
| Basal Coverage | Ultra‑long‑acting, peakless >24 h | Depends on basal insulin used |
| Prandial Coverage | Rapid‑acting, suppresses post‑meal spikes | Rapid‑acting bolus at mealtimes |
| Component Interference | None – independently stable | N/A (separate injections) |
| Patient Convenience | Higher (fewer injections, simpler titration) | Lower (complex regimen) |
The dual insulin analogue class represents an evolving approach to insulin therapy, offering the pharmacological benefits of both basal and prandial insulin in a single, co‑formulated product. This addresses a well‑documented barrier in diabetes management – regimen complexity – which contributes to poor adherence and suboptimal glycemic control in real‑world clinical practice.
Market Impact & Outlook
- China Diabetes Landscape: China has the world’s largest diabetic population, with over 140 million adults living with diabetes. Insulin therapy remains a cornerstone of treatment for type 1 and advanced type 2 diabetes, creating substantial demand for next‑generation insulin formulations.
- Domestic Insulin Market: The Chinese insulin market has been dominated by multinational players (Novo Nordisk, Sanofi, Eli Lilly). Sunshine Lake Pharma’s approval of a domestically developed dual insulin analogue strengthens the import‑substitution narrative and adds competitive pressure on established brands.
- Product Differentiation: The dual‑action, single‑formulation design offers a clinically meaningful convenience advantage over separate basal‑bolus regimens, potentially driving adoption among patients and prescribers seeking simplified insulin therapy.
- Commercial Platform: Approval in both cartridge and pre‑filled pen formats ensures compatibility with existing insulin delivery devices and aligns with the growing preference for pre‑filled pen devices in both hospital and outpatient settings.
- Sunshine Lake Pharma’s Pipeline: This approval adds to the company’s growing portfolio in metabolic diseases, reinforcing its positioning as a leading Chinese biopharma with capabilities spanning biologics and complex formulations.
- Revenue Potential: Specific commercialization timelines, pricing, and sales projections Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial launch, market adoption, and clinical utilization of Insulin Degludec and Insulin Aspart Injection in China. Actual outcomes may differ due to risks including provincial procurement processes, formulary inclusion timelines, competitive dynamics, pricing negotiations, and the inherent uncertainties of pharmaceutical commercialization.-Fineline Info & Tech
